{Reference Type}: Journal Article
{Title}: Recent and anticipated novel drug approvals (Q2 2024 through Q1 2025).
{Author}: Rim MH;Karas BL;Barada F;Dean C;Levitsky AM;
{Journal}: Am J Health Syst Pharm
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 4
{Factor}: 2.98
{DOI}: 10.1093/ajhp/zxae148
{Abstract}: <B>CONCLUSIONS: </B>In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.<BR><B>OBJECTIVE: </B>Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing periodic updates on new and anticipated novel drug approvals.<BR><B>CONCLUSIONS: </B>Selected drug approvals anticipated in the 12-month period covering the second quarter of 2024 through the first quarter of 2025 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from 52 novel drugs awaiting US Food and Drug Administration approval. New cellular and gene therapies for cancers continued to strengthen the pipeline, in addition to new drugs targeting previously untreatable conditions. Several novel drugs are being developed for rare and ultra-rare diseases such as hemophilia, Niemann-Pick disease type C, hereditary angioedema, and aromatic L-amino acid decarboxylase deficiency.<BR><B>CONCLUSIONS: </B>The current drug pipeline includes new drugs with various indications for cancers and rare diseases as well as diabetes, acute coronary syndrome, chronic skin disorder, and chronic obstructive pulmonary disease.